Core Insights - Chicago Atlantic BDC, Inc. reported quarterly earnings of $0.42 per share, exceeding the Zacks Consensus Estimate of $0.35 per share, and showing a significant improvement from break-even earnings per share a year ago, resulting in an earnings surprise of +20.00% [1] - The company achieved revenues of $15.07 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 11.97%, compared to revenues of $3.18 million in the same quarter last year [2] - The stock has underperformed the market, losing about 17.6% since the beginning of the year, while the S&P 500 has gained 16.5% [3] Earnings Outlook - The earnings outlook for Chicago Atlantic BDC is mixed, with current consensus EPS estimates at $0.35 for the coming quarter and $1.41 for the current fiscal year, with revenues expected to be $13.99 million and $52.46 million respectively [7] - The company's Zacks Rank is currently 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Industry Context - The Financial - SBIC & Commercial Industry, to which Chicago Atlantic BDC belongs, is currently ranked in the bottom 20% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment [5]

Core Viewpoint - Afya reported quarterly earnings of $0.38 per share, exceeding the Zacks Consensus Estimate of $0.32 per share, marking an earnings surprise of +18.75% [1][2] Financial Performance - The company posted revenues of $170.44 million for the quarter ended September 2025, which was slightly below the Zacks Consensus Estimate by 0.16%, compared to $151.71 million in the same quarter last year [2] - Over the last four quarters, Afya has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Afya shares have declined approximately 9.1% since the beginning of the year, while the S&P 500 has gained 16.4% [3] - The current Zacks Rank for Afya is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.40 on revenues of $172.53 million, and for the current fiscal year, it is $1.71 on revenues of $687.12 million [7] - The trend of estimate revisions for Afya was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Schools industry, to which Afya belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Core Insights - KORU Medical Systems, Inc. reported a quarterly loss of $0.02 per share, better than the Zacks Consensus Estimate of a loss of $0.03, marking an earnings surprise of +33.33% [1] - The company achieved revenues of $10.4 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 7.07% and showing a year-over-year increase from $8.18 million [2] - The stock has underperformed the market, losing approximately 3.1% year-to-date compared to the S&P 500's gain of 16.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $10.52 million, and for the current fiscal year, it is -$0.08 on revenues of $40.1 million [7] - The estimate revisions trend for KORU Medical Systems was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical Info Systems industry, to which KORU Medical Systems belongs, is currently ranked in the top 20% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Phreesia, is expected to report a quarterly loss of $0.01 per share, reflecting a year-over-year change of +96%, with revenues projected at $120.19 million, up 12.5% from the previous year [9][10]

Core Insights - PLBY Group, Inc. reported quarterly earnings of $0.02 per share, surpassing the Zacks Consensus Estimate of a loss of $0.02 per share, and showing a significant improvement from a loss of $0.45 per share a year ago, resulting in an earnings surprise of +200.00% [1] - The company generated revenues of $28.99 million for the quarter ended September 2025, which was 2.05% below the Zacks Consensus Estimate, but an increase from $12.86 million in the same quarter last year [2] - PLBY Group shares have declined approximately 7.5% year-to-date, contrasting with the S&P 500's gain of 16.4% [3] Earnings Outlook - The future performance of PLBY Group's stock will largely depend on management's commentary during the earnings call and the revisions of earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is breakeven on $36 million in revenues, while for the current fiscal year, it is projected at -$0.19 on $122.6 million in revenues [7] Industry Context - The Leisure and Recreation Products industry, to which PLBY Group belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]

分组1 - Silvaco Group, Inc. reported a quarterly loss of $0.07 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.06, marking an earnings surprise of -16.67% [1] - The company posted revenues of $18.67 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 16.19%, compared to $10.97 million in the same quarter last year [2] - Silvaco Group, Inc. shares have declined approximately 39.9% year-to-date, contrasting with the S&P 500's gain of 16.4% [3] 分组2 - The earnings outlook for Silvaco Group, Inc. is uncertain, and future stock performance will depend on management's commentary during the earnings call [4] - The current consensus EPS estimate for the upcoming quarter is $0.26 on revenues of $24.8 million, while for the current fiscal year, it is -$0.02 on revenues of $67.01 million [7] - The Electronics - Semiconductors industry, to which Silvaco belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Core Insights - Snail, Inc. reported a quarterly loss of $0.21 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.05, marking an earnings surprise of -320.00% [1] - The company's revenues for the quarter ended September 2025 were $13.82 million, missing the Zacks Consensus Estimate by 37.18% and down from $22.53 million a year ago [2] - Snail, Inc. shares have declined approximately 48.3% year-to-date, contrasting with the S&P 500's gain of 16.4% [3] Financial Performance - Over the last four quarters, Snail, Inc. has surpassed consensus EPS estimates two times [2] - The current consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $30 million, while for the current fiscal year, it is -$0.48 on revenues of $94.3 million [7] Market Outlook - The company's earnings outlook will be crucial for future stock performance, with management's commentary on the earnings call expected to influence investor sentiment [3][4] - The Zacks Rank for Snail, Inc. is currently 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Industry Context - The Gaming industry, to which Snail, Inc. belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Another company in the same industry, GDEV Inc., is expected to report quarterly earnings of $0.42 per share, reflecting a year-over-year decline of 46.8% [9]

分组1 - Pulmonx Corporation reported a quarterly loss of $0.34 per share, which was better than the Zacks Consensus Estimate of a loss of $0.40, representing an earnings surprise of +15.00% [1] - The company achieved revenues of $21.5 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 4.10% and showing an increase from $20.39 million year-over-year [2] - Over the last four quarters, Pulmonx has consistently surpassed consensus EPS and revenue estimates [2] 分组2 - The stock has underperformed significantly, losing about 69.2% since the beginning of the year, while the S&P 500 has gained 16.4% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of $23.83 million, and for the current fiscal year, it is -$1.51 on revenues of $90.89 million [7] - The Medical Info Systems industry, to which Pulmonx belongs, is currently ranked in the top 20% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Core Insights - iBio, Inc. reported a quarterly loss of $0.11 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.07, marking an earnings surprise of -57.14% [1] - The company generated revenues of $0.1 million for the quarter ended September 2025, consistent with the Zacks Consensus Estimate, compared to zero revenues a year ago [2] - iBio shares have declined approximately 49.4% year-to-date, contrasting with the S&P 500's gain of 16.4% [3] Company Performance - Over the last four quarters, iBio has exceeded consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $0.1 million, and for the current fiscal year, it is -$0.40 on revenues of $0.5 million [7] - The estimate revisions trend for iBio was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which iBio belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.2 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -66.67%. A quarter ago, it was expected that this company would post a loss of $0.09 per share when it actually produced a loss of $0.1, delivering a surprise of -11.11%.Over the last four quarters, the company has ...

Core Insights - Astria Therapeutics reported a quarterly loss of $0.55 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.41, marking an earnings surprise of -34.15% [1] - The company generated revenues of $0.71 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 95.59%, compared to zero revenues a year ago [2] - The stock has increased approximately 39.9% year-to-date, outperforming the S&P 500's gain of 16.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.59 on $2 million in revenues, and for the current fiscal year, it is -$2.09 on $17 million in revenues [7] - The estimate revisions trend for Astria Therapeutics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Astria Therapeutics belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Aytu BioPharma Inc., another company in the same industry, is expected to report a quarterly loss of $0.06 per share, reflecting a year-over-year change of +70% [9]